Severe bronchospasm associated with rituximab for refractory Churg–Strauss syndrome
Department of Internal Medicine, French Vasculitis Study Group, Hôpital Cochin, Université Paris 5–René Descartes, Paris, France
Correspondence to:
Dr M-A Bouldouyre, Department of Internal Medicine, French Vasculitis Study Group, Hôpital Cochin, Université Paris 5–René Descartes, Paris, France; marie-anne.bouldouyre@cch.aphp.fr
Accepted 26 July 2008
| The first 150 words of the full text of this article appear below. |
Rituximab is now used to control antineutrophil cytoplasm antibody (ANCA)-associated vasculitides, eg, Wegeners granulomatosis.1 2 In Churg–Strauss syndrome (CSS), a small-vessel systemic vasculitis with asthma and eosinophilia, 39% of patients have ANCA.3 4 Rituximab could be effective in ANCA-associated vasculitides, even if ANCA are not present at the time of prescription, because B lymphocytes also play a role as antigen-presenting cells and can modulate the immune response in another way than targeting antibody production. Therapy-refractory CSS5 was successfully treated with rituximab in three patients.6–8 We would like to draw attention to the potential risk of rituximab-associated bronchospasm, by reporting our experience with two CSS patients.
A 44-year-old woman had been treated for CSS for 2 years. Her initial symptoms included: paranasal sinusitis; persistent cough; weight loss; asthma; hypereosinophilia and bilateral pulmonary infiltrates. ANCA were negative. Despite high-dose corticosteroids, she was hospitalised in extremis three times for severe asthma. Azathioprine then methotrexate were
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
